Endothelial dysfunction and pathogenesis of diabetic angiopathy

Cardiovascular Research

Volumn 34, Issue 1, 1997, Pages 55-68

  Stehouwer, Coen D A ^a   Lambert, Jan ^a   Donker, A J M ^a   Van Hinsbergh, Victor W M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Diabetes; Diabetic angiopathy; Endothelium; Human; Hyperglycemia; Insulin; Non enzymatic glycation

Indexed keywords

INSULIN; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; ENDOTHELIUM; ENZYME ACTIVATION; GENE EXPRESSION; GLYCATION; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 0030976646     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00272-6     Document Type: Review

References (154)

1. Deckert T, Yokoyama H, Mathiesen E, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Br Med J 1996;312:871-874.
2. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in non-insulin-dependent diabetes mellitus. Diabetes 1995;44:1301-1309.
3. Stehouwer CDA, Schaper NC. The pathogenesis of vascular complications of diabetes mellitus: one voice or many? Eur J Clin Invest 1996;26:535-543.
4. Stehouwer CDA. Von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complications in diabetes. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus, 3rd edn. Boston: Kluwer, 1997:155-163.
5. Stehouwer CDA, Donker AJM. Urinary albumin excretion and cardiovascular disease risk in diabetes mellitus: Is endothelial dysfunction the missing link? J Nephrol 1993;6:72-92.
6. Vane JR, Ånggård EE, Botting RM. Mechanisms of disease: regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
7. Renkin EM. Capillary transport of macromolecules: pores and other endothelial pathways. J Appl Physiol 1985;58:315-325.
8. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-451.
9. van Hinsbergh VWM, ed. Vascular Control of Hemostasis. Advances in Vascular Biology (Vadas MA, Harlan J, series eds.), Vol 1. Amsterdam: Harwood Academic Publishers, 1996.
10. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677-678.
11. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-355.
12. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
13. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-1579.
14. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
15. Blann AD, Taberner DA. A reliable marker of endothelial dysfunction: does it exist? Br J Haematol 1995;90:244-248.
16. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996;2:800-803.
17. Meyer D, Girma JP. von Willebrand factor: Structure and function. Thromb Haemost 1993;70:111-118.
18. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
19. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988;33:917-924.
20. Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, den Ottolander GJH. von Willebrand factor and development of diabetic nephropathy in insulin-dependent diabetes mellitus. Diabetes 1991;40:971-976 [erratum, Diabetes 1991;40:1746].
21. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 1996;92:747-750.
22. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci 1993;83:687-693.
23. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Albuminuria, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319-323.
24. Plater ME, Ford I, Dent MT, Preston FE, Ward JE. Elevated von Willebrand factor antigen predicts deterioration in diabetic periperal nerve function. Diabetologia 1996;39:336-343.
25. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;i:461-463.
26. Stehouwer CDA, Zellenrath P, Polak BCP, Baarsma GS, Nauta JJP, Donker AJM, den Ottolander GJH. von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with Type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia 1992;35:555-559.
27. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polak BCP, Donker AJM. Endothelial dysfunction precedes development of microalbuminuria in insulin-dependent diabetes mellitus. Diabetes 1995;44:561-564.
28. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-2554.
29. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.
30. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes 1995;44:721-726.
31. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813.
32. Lambert J, Aarsen M, Donker AJM, Stehouwer CDA. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscl Thromb Vase Biol 1996;16:705-711.
33. Smits P, Kapma J, Jacobs MC, Lutterman J, Thien T. Endothelium-dependent vascular relaxation in patients with Type 1 diabetes. Diabetes 1993;42:148-153.
34. Smulders RA, Stehouwer CDA, Olthof CG, et al. Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin Sci 1994;87:37-43.
35. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994;43:1190-1197.
36. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995;88:245-255.
37. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993;87(suppl V):V67-V76.
38. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-1165.
39. Earle K, Walker J, Hill C, Viberti GC. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992;326:673-677.
40. DeFronzo RA, Ferranini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
41. Chen JW, Gall MA, Deckert M, Jensen JS, Parving HH. Increased serum concentration of von Willebrand factor in non-insulin-dependent diabetic patients with and without diabetic nephropathy. Br Med J 1995;311:1405-1406.
42. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
43. Goodfellow J, Ramsey MW, Luddington LA, et al. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. Br Med J 1996;312:744-745.
44. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and -independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-776.
45. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with non-insulin-dependent diabetes mellitus. Diabetologia 1995;38:1337-1344.
46. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306-310.
47. Juhan-Vague I, Vague P. Hyperinsulinemia and its effects on coagulation and fibrinolysis in cardiovascular disease. In: Francis RB, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker, 1992:141-182.
48. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70:380-385.
49. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179.
50. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-2515.
51. Baron AD. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996;45(suppl.l):S105-S109.
52. Ferri C, Bellini C, Desideri G, et al. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 1995;44:431-436.
53. Miles PDG, Levisetti M, Reichart D, Khoursheed M, Moosa AR, Olefsky JM. Kinetics of insulin action in vivo. Identification of rate limiting steps. Diabetes 1995;44:947-953.
54. Yang YJ, Hope ID, Ader M, Bergman R. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 1989;84:1620-1628.
55. Jansson PE, Fowelin JP, Von Schenk HP, Smith UP, Lonnroth PN. Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Diabetes 1993;42:1469-1473.
56. Castillo C, Bogardus C, Bergman R, Thuillez P, Lillioja S. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest 1994;93:10-16.
57. Ader M, Bergman RN. Importance of transcapillary insulin transport to dynamics of insulin action after intravenous glucose. Am J Physiol 1994;266:E17-E25.
58. Utriainen T, Malmström R, Mäkimattila S, Yki-Järvinen H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 1995;38:555-564.
59. 18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 1996;97:1741-1747.
60. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome? Diabetes 1997 (in press).
61. Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1995;92:983-987.
62. Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diabetes Metab Rev 1992;8:85-103.
63. Baumgartner-Parzer SM, Wagner L, Pettermann M, Grillari J, Gessl A, Waldhäusl W. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 1995;44:1323-1327.
64. 2 in high-glucose medium. Diabetes 1995;44:520-526.
65. Anderson MT, Staal FJT, Gitler C, Herzenberg LA, Herzenberg LA. Separation of oxidant-initiated and redox-regulated steps in the NF-kB signal transduction pathway. Proc Natl Acad Sci USA 1994;91:11527-11531.
66. DeRubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994;43:1-8.
67. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994;45:179-188.
68. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCß inhibitor. Science 1996;272:728-731.
69. Williams B. Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J Hypertens 1995;13:477-486.
70. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat vascular smooth muscle cells exposed to elevated glucose levels. Diabetes 1994;43:1372-1377.
71. Porte D, Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science 1996;272:699-670.
72. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator. Diabetes 1995;44:1139-1146.
73. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
74. Yoshioka K, Takemura T, Murakami K, et al. Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154-163.
75. Kim SJ, Guck A, Sporn MB, Roberts AB. Characterisation of the promoter region of the human transforming growth factor-βl gene. J Biol Chem 1989;264:402-408.
76. MacKay K, Striker L, Stauffer JW, Doi T, Agodoa LY, Striker GE. Transforming growth factor-β: murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest 1989;83:160-167.
77. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689-695.
78. Suzuki S, Ebihara I, Tomino Y, Koide H. Transcriptional activation of matrix genes by transforming growth factor beta 1 in mesangial cells. Exp Nephrol 1993;1:229-237.
79. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987;105:957-963.
80. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
81. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
82. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482.
83. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
84. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in nonhuman primate. Arch Ophthalmol 1996;114:964-970.
85. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
86. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
87. Williamson JR, Chang KC, LeJeune W, Stephan CC, Brock TA, Tilton RG. Links between retinal vascular dysfunction induced by elevated glucose levels and VEGF. Invest Ophthalmol Vis Sci 1996;37:S969.
88. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995;92:768-772.
89. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-6274.
90. Punglia R, Kuroki M, Tolentino MJ, et al. IGF-1 increases VEGF mRNA and secreted protein in retinal cells. Invest Ophthalmol Vis Sci 1996;37:S794.
91. Brownlee M. Glycation and diabetic complications. Diabetes 1994;43:836-841.
92. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-151.
93. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-683.
94. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994;91:7742-7746.
95. Lo TWC, Westwood ME, McLellan AC, Selwood T, Thornally PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. J Biol Chem 1994;269:32299-32305.
96. Thornally PJ. Methylglyoxal, glyoxylases and the development of diabetic complications. Amino Acids 1994;6:15-23.
97. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycation endproducts in vivo. J Biol Chem 1992;267:5133-5138.
98. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science 1992;258:651-653.
99. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996;347:513-515.
100. McLellan AC, Philips SA, Thornally PJ. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. Anal Biochem 1992;206:17-23.
101. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.
102. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-9445.
103. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654-667.
104. Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl Thromb Vase Biol 1995;15:571-582.
105. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffe S. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708.
106. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992;89:12043-12047.
107. ElKhoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silver-stein SC. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994;269:10197-10200.
108. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-438.
109. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.
110. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994;91:8807-8811.
111. Schmidt AM, Pinsky D, Kao J, et al. Environmental perturbation of endothelium: modulation of vascular properties by hypoxia, hyperglycemia and tumor-derived cytokines. In: Van Hinsbergh VWM, ed. Vascular Control of Hemostasis. Amsterdam: Harwood Academic Publishers, 1996:257-279.
112. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91:9436-9440.
113. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb Vase Biol 1994;14:1521-1528.
114. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989;170:1387-1407.
115. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395-1403.
116. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-243.
117. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994;94:110-117.
118. Tezuka M, Koyama N, Morisaki N, et al. Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical vein endothelial cells. Biochem Biophys Res Comm 1993;193:674-680.
119. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824-829.
120. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
121. Ceriello A, dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 1996;45:471-477.
122. Nouroz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in non-insulin-dependent diabetes mellitus. Diabetes 1995;44:1054-1058.
123. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-1125.
124. Krugluger W, Kopp HP, Schernthaner G, Hopmeier P. Enhanced anticoagulant response to activated protein C in patients with insulin-dependent diabetes mellitus. Diabetes 1995;44:1033-1037.
125. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscl Thromb Vase Biol 1995;15:1114-1120.
126. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor activity in patients with insulin-dependent diabetes mellitus. Diabetes 1995;44:80-84.
127. Myrup B, Rossing P, Jensen T, Gram J, Kluft C, Jespersen J. Procoagulant activity and intimal dysfunction in insulin-dependent diabetes mellitus. Diabetologia !995;38:73-78.
128. Gruden G, Cavallo-Perin P, Bazzab M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in insulin-dependent diabetes mellitus patients with microalbuminuria. Diabetes 1994;43:426-429.
129. Kofoed-Enevoldsen A. Inhibition of glomerular glucosaminyl N-deacetylase in diabetic rats. Kidney Int 1992;41:763-767.
130. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995;44:924-928.
131. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987;79:117-123.
132. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
133. Saghizadeh M, Ong JM, Garvey TM, Henry RR, Kern PA. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest 1996;97:1111-1116.
134. Hotamisligil GS, Budavari A, Murray DL, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest 1994;94:1543-1549.
135. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. 1RS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996;271:665-668.
136. McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989;38:1042-1046.
137. Mendall MA, Patel P, Ballam LD, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996;312:1061-1065.
138. Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischaemic heart disease. Br Med J 1996;312:1049-1050.
139. Hattori Y, Kasai K, Nakamura T, Emoto T, Shimodi SI. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism 1991;40:165-169.
140. Wolpert HA, Steen SN, Istfan NW, Simonson DW. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 1993;42:1027-1030.
141. Polderman KH, Stehouwer CDA, van Kamp GJ, Gooren LJG. Effects of insulin infusion on endothelium-derived vasoactive substances. Diabetologia 1996;39:1284-1292.
142. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994;89:321-330.
143. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol 1996;7:217-226.
144. Bhanot S, McNeill JH. Insulin and hypertension: a causal relationship? Cardiovasc Res 1996;31:212-221.
145. Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 1992;21:136-141.
146. Rakugi H, Yu H, Kamitani A, et al. Links between hypertension and myocardial infarction. Am Heart J 1996;132:213-221.
147. Dominiczak AF, Bohr DF. Nitric oxide and hypertension in 1995. Curr Opin Nephrol Hypertens 1996;5:174-180.
148. Lüscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol 1996;7:234-240.
149. Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol 1995;6:190-195.
150. Saxena U, Goldberg IJ. Endothelial cells and atherosclerosis: lipoprotein metabolism, matrix interactions, and monocyte recruitment. Curr Opin Lipidol 1994;5:316-322.
151. Campbell JH, Campbell GR. The role of smooth muscle cells in atherosclerosis. Curr Opin Lipidol 1994;5:323-330.
152. Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of Type 1 (insulin-dependent) diabetic patients. Diabetologia 1992;35:1151-1158.
153. Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in pa-tients with insulin dependent diabetes mellitus and microalbuminuria. Br Med J 1995;311:973-977.
154. Knöbl P, Schernthaner G, Schnack C, et al. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994;71:692-697.